CLINICAL TRIALS PROFILE FOR GLUCOPHAGE

« Back to Dashboard

505(b)(2) Clinical Trials for GLUCOPHAGE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Indication	NCT03831464 ↗	Metformin as RenoProtector of Progressive Kidney Disease	Recruiting	University Hospital, Antwerp	Phase 3	2019-11-05	A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant for more than 3 years).
New Indication	NCT03831464 ↗	Metformin as RenoProtector of Progressive Kidney Disease	Recruiting	Tess Wuyts	Phase 3	2019-11-05	A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant for more than 3 years).
New Indication	NCT03831464 ↗	Metformin as RenoProtector of Progressive Kidney Disease	Recruiting	Universiteit Antwerpen	Phase 3	2019-11-05	A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant for more than 3 years).

All Clinical Trials for GLUCOPHAGE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00032474 ↗	Ginkgo Biloba Extract and the Insulin Resistance Syndrome	Completed	National Center for Complementary and Integrative Health (NCCIH)	Phase 1/Phase 2	2001-12-01	The purpose of this study is to examine whether the ingestion of the herbal dietary supplement Ginkgo biloba extract has any effect on the efficacy of three classes of diabetic medications - (Glucotrol, Glucophage and Actose). Additionally, the study will examine the effect of Ginkgo biloba extract on pancreatic insulin production in non-diabetic subjects between the ages of 20 and 75 years old.
NCT00038727 ↗	Diabetes Prevention Program Outcomes Study	Active, not recruiting	American Diabetes Association	Phase 3	2002-09-01	The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations. The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
NCT00038727 ↗	Diabetes Prevention Program Outcomes Study	Active, not recruiting	Centers for Disease Control and Prevention	Phase 3	2002-09-01	The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations. The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
NCT00038727 ↗	Diabetes Prevention Program Outcomes Study	Active, not recruiting	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	2002-09-01	The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations. The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
NCT00038727 ↗	Diabetes Prevention Program Outcomes Study	Active, not recruiting	General Clinical Research Program	Phase 3	2002-09-01	The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations. The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
NCT00038727 ↗	Diabetes Prevention Program Outcomes Study	Active, not recruiting	Indian Health Service	Phase 3	2002-09-01	The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations. The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.

Clinical Trial Conditions for GLUCOPHAGE

Condition Name

Condition Name for GLUCOPHAGE
Intervention	Trials
Healthy	36
Type 2 Diabetes Mellitus	34
Type 2 Diabetes	28
Diabetes Mellitus, Type 2	22

Condition MeSH

Condition MeSH for GLUCOPHAGE
Intervention	Trials
Diabetes Mellitus	94
Diabetes Mellitus, Type 2	82
Insulin Resistance	24
Polycystic Ovary Syndrome	21

Clinical Trial Locations for GLUCOPHAGE

Trials by Country

Trials by Country for GLUCOPHAGE
Location	Trials
United States	456
China	99
Canada	41
India	25
United Kingdom	21

Trials by US State

Trials by US State for GLUCOPHAGE
Location	Trials
Texas	34
California	33
Ohio	22
Pennsylvania	21
New York	20

Clinical Trial Progress for GLUCOPHAGE

Clinical Trial Phase

Clinical Trial Phase for GLUCOPHAGE
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
Phase 4	66

Clinical Trial Status

Clinical Trial Status for GLUCOPHAGE
Clinical Trial Phase	Trials
Completed	210
Recruiting	39
Unknown status	34

Clinical Trial Sponsors for GLUCOPHAGE

Sponsor Name

Sponsor Name for GLUCOPHAGE
Sponsor	Trials
National Cancer Institute (NCI)	22
AstraZeneca	20
Merck Sharp & Dohme Corp.	19

Sponsor Type

Sponsor Type for GLUCOPHAGE
Sponsor	Trials
Other	389
Industry	171
NIH	66

Glucophage Clinical Trials, Market Analysis, Patent Status and Forecast

Last updated: July 31, 2026

Glucophage is the original branded formulation of metformin, an oral biguanide used primarily for type 2 diabetes. Its commercial value now comes mainly from the broader metformin market, not from branded Glucophage sales. Core patent and regulatory exclusivity expired years ago, generic competition is extensive, and no biosimilar pathway applies. Clinical development has shifted from proving glucose-lowering efficacy to testing metformin in obesity-related disease, polycystic ovary syndrome, cancer prevention, infectious disease and aging.

What is Glucophage and how is it used?

Glucophage contains metformin hydrochloride. Immediate-release tablets are generally administered two or three times daily, while Glucophage XR uses an extended-release formulation for once-daily or reduced-frequency dosing.

Attribute	Glucophage
Active ingredient	Metformin hydrochloride
Drug class	Biguanide antihyperglycemic
Original developer	Merck & Co.
U.S. approval	1994
Main indication	Type 2 diabetes mellitus
Main mechanism	Reduced hepatic glucose production; improved insulin sensitivity
Dosage forms	Immediate-release and extended-release tablets
Biosimilar status	Not applicable
Generic status	Widely available
U.S. market position	Generic-dominated
Primary safety restriction	Metformin-associated lactic acidosis risk, particularly with severe renal impairment

Metformin remains a first-line pharmacologic treatment for many adults with type 2 diabetes because of low cost, long-term clinical experience, weight neutrality or modest weight reduction, and a low risk of hypoglycemia when used without insulin or insulin secretagogues. The American Diabetes Association continues to list metformin among the principal glucose-lowering options, although treatment selection is increasingly influenced by cardiovascular, renal and weight-management benefits associated with newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors (American Diabetes Association Professional Practice Committee, 2024).

What is the FDA regulatory status of Glucophage?

The FDA approved Glucophage tablets in 1994 and Glucophage XR in 2000. The drug is approved for glycemic control in adults and pediatric patients with type 2 diabetes, subject to product-specific labeling.

The U.S. label includes renal-function restrictions. Metformin is contraindicated in patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m². Initiation is generally not recommended at an eGFR between 30 and 45, and continued treatment requires reassessment when renal function falls within that range (FDA, 2023).

The principal FDA regulatory developments affecting metformin have involved safety and manufacturing controls rather than new indications:

• Expanded renal-function guidance.
• Temporary or permanent recalls of selected products because of nitrosamine contamination.
• Labeling and monitoring requirements related to lactic acidosis.
• Continued approval of multiple abbreviated new drug application products.

The FDA has not approved Glucophage for weight loss, cancer prevention, anti-aging treatment, infertility, polycystic ovary syndrome or COVID-19 treatment.

When did Glucophage lose exclusivity?

Glucophage lost meaningful U.S. market exclusivity after generic metformin approvals began in the 2000s. The original immediate-release product and the extended-release product no longer have commercially meaningful regulatory exclusivity.

Exclusivity category	Glucophage status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	None
Pediatric exclusivity	Expired or not commercially material
U.S. patent exclusivity	Expired for core products
180-day generic exclusivity	Long expired for the original products
Biosimilar exclusivity	Not applicable

Merck does not report standalone current revenue for Glucophage in its public financial filings. The brand has been displaced by generic immediate-release and extended-release metformin manufactured by numerous companies.

What patents protect Glucophage?

No active core U.S. patent estate is generally recognized as a material barrier to generic entry for standard Glucophage immediate-release or extended-release tablets.

The commercial protection historically associated with Glucophage included:

• Composition and formulation patents for metformin products.
• Extended-release delivery technology for Glucophage XR.
• Manufacturing and tablet-processing claims.
• Regulatory exclusivity linked to the original approvals.

Those protections have expired or lost practical significance because generic manufacturers now market both immediate-release and extended-release metformin products.

Are formulation patents still relevant?

Formulation patents can remain relevant for specific modified-release products, but they do not restore exclusivity to the original Glucophage franchise. A manufacturer may obtain patents covering a particular matrix, granulation process, release profile or excipient combination. Such patents can affect individual generic products without preventing the sale of metformin generally.

The strongest remaining intellectual-property positions in the metformin field are more likely to involve:

• Combination products.
• Fixed-dose formulations with newer diabetes drugs.
• Controlled-release delivery systems.
• Pediatric or liquid formulations.
• Novel uses supported by new clinical evidence.

These rights would generally protect a specific product or use, not the active ingredient itself.

What clinical trials are evaluating metformin?

The metformin clinical-trial pipeline is active but fragmented. Most studies evaluate repurposing opportunities rather than improvements to Glucophage itself.

Diabetes prevention and progression

The Diabetes Prevention Program showed that metformin reduced progression from impaired glucose tolerance to type 2 diabetes, particularly in younger adults, people with higher body mass index and women with a history of gestational diabetes (Diabetes Prevention Program Research Group, 2002).

The Diabetes Prevention Program Outcomes Study has followed participants for years and has reported sustained, though attenuated, reductions in diabetes incidence after the original intervention period. These findings support long-term preventive use in selected high-risk patients, but the FDA has not approved metformin specifically for diabetes prevention.

Polycystic ovary syndrome

Metformin is widely used off label in polycystic ovary syndrome, especially where insulin resistance, impaired glucose tolerance or metabolic risk is present. Trials have evaluated menstrual regularity, ovulation, fertility, pregnancy outcomes and metabolic parameters.

Clinical evidence supports selected use, but metformin is not a general-purpose fertility drug. Its role is narrower than that of ovulation-induction agents such as letrozole. Guidelines generally position metformin as a metabolic treatment or adjunct rather than the preferred first-line ovulation therapy in all patients.

COVID-19

The COVID-OUT trial evaluated metformin, ivermectin and fluvoxamine in adults with overweight or obesity who had early symptomatic COVID-19. In the trial, metformin reduced the composite outcome of emergency-department visit, hospitalization or death compared with placebo (Bramante et al., 2022).

The result did not lead to FDA approval for COVID-19. The study was important for repurposing research but did not create a new commercial indication for Glucophage.

Cancer prevention and treatment

Metformin has been studied in breast, colorectal, endometrial, pancreatic and other cancers. Observational studies have often suggested lower cancer incidence or improved outcomes among diabetic metformin users. Randomized trials have produced less consistent results.

The main development problem is biological heterogeneity. Metformin exposure in tumors may be lower than concentrations used in laboratory studies, and outcomes may depend on diabetes status, tumor metabolism, molecular subtype and concurrent treatment. No cancer indication has been approved for Glucophage.

Aging and geroscience

The Targeting Aging with Metformin concept has generated substantial academic interest. The proposed rationale is that metformin may affect insulin signaling, inflammation, mitochondrial function and age-related disease pathways.

A definitive FDA-recognized anti-aging indication does not exist. The clinical development challenge is endpoint selection. A trial would need to show effects across multiple age-related diseases or a validated composite endpoint rather than a change in a single biomarker.

Weight management and metabolic disease

Metformin can produce modest weight reduction in some patients, particularly those with insulin resistance, prediabetes or antipsychotic-associated weight gain. Its average effect is materially smaller than that of semaglutide, tirzepatide and other modern obesity therapies.

Metformin is therefore more likely to remain a low-cost adjunct or treatment for selected metabolic phenotypes than to become a direct competitor to branded incretin therapies.

What is the competitive landscape for Glucophage?

Glucophage competes in two distinct markets: the low-cost metformin market and the broader type 2 diabetes market.

Generic metformin competitors

Immediate-release and extended-release metformin are supplied by multiple generic manufacturers, including large contract and finished-dose producers. Price competition is intense, and product differentiation is limited.

Potential competitive factors include:

• Tablet tolerability.
• Once-daily dosing.
• Availability during supply disruptions.
• Quality-control performance.
• Nitrosamine testing.
• Hospital and pharmacy contracts.
• Geographic manufacturing diversity.

Newer diabetes therapies

Metformin faces clinical competition from:

• SGLT2 inhibitors such as empagliflozin and dapagliflozin.
• GLP-1 receptor agonists such as semaglutide.
• Dual GIP/GLP-1 agonists such as tirzepatide.
• DPP-4 inhibitors.
• Basal insulin and other insulin products.

The newer therapies command substantially higher prices and offer benefits that metformin does not consistently provide, including greater weight loss and cardiovascular or renal risk reduction in defined populations. They have not eliminated metformin because of the large global diabetes population, low acquisition cost and broad familiarity.

How large is the metformin market?

Glucophage-specific revenue is not publicly separated from Merck’s broader product reporting. Market estimates therefore generally refer to metformin or the metformin hydrochloride market rather than the Glucophage brand.

Commercial market reports place the global metformin market in the low-single-digit billions of U.S. dollars in the early 2020s, with projections toward the mid-single-digit billions by the end of the decade. Estimates vary because some reports count active pharmaceutical ingredient sales, while others count finished-dose products or the full diabetes-treatment segment (Grand View Research, 2024; Fortune Business Insights, 2024).

Market driver	Effect on metformin
Rising type 2 diabetes prevalence	Positive volume growth
Generic pricing	Negative revenue growth
Expansion in emerging markets	Positive unit growth
GLP-1 and SGLT2 adoption	Negative share pressure in higher-income markets
Low-cost public-health programs	Positive access and volume
Nitrosamine recalls	Short-term supply disruption risk
Combination therapy use	Supports continued prescribing

Unit demand should grow faster than branded revenue. The principal reason is rising diabetes prevalence in Asia, Latin America, the Middle East and Africa, combined with low generic prices.

What is the market projection for Glucophage and metformin through 2030?

The base-case outlook is continued volume growth with limited pricing power.

Base-case projection

• Global metformin unit demand: mid-single-digit annual growth, driven by diabetes prevalence and diagnosis.
• Global metformin revenue: low- to mid-single-digit annual growth, depending on geographic mix.
• Branded Glucophage revenue: flat to declining in markets where generic substitution is complete.
• Extended-release metformin: faster growth than immediate-release tablets in markets where adherence and gastrointestinal tolerability are valued.
• Combination products: higher commercial growth than standalone Glucophage.
• U.S. revenue: largely genericized and exposed to price compression.
• Emerging-market revenue: more favorable volume dynamics but lower average selling prices.

The most credible commercial opportunity is not a return of the original Glucophage brand. It is the use of metformin as a low-cost foundation in combination with newer drugs, particularly where payers require step therapy or patients cannot afford branded therapies.

What generic entry risks exist for Glucophage?

Generic entry risk is no longer a future event for the original product. It is the current market structure.

The main risks to any residual Glucophage sales are:

1. Automatic generic substitution.
2. Pharmacy benefit manager pricing pressure.
3. Multiple-source supply contracts.
4. Product recalls linked to nitrosamine findings.
5. Switching to other manufacturers of extended-release metformin.
6. Loss of prescriber attention to branded products.

A generic manufacturer does not need to overcome a live Glucophage composition patent to enter the market. For standard tablets, the primary requirements are ANDA approval, bioequivalence, manufacturing compliance and reliable supply.

What is the biosimilar risk for Glucophage?

There is no biosimilar risk because metformin is a chemically synthesized small molecule. The relevant pathway is the generic-drug pathway under an ANDA, not the biologics license application and biosimilar pathway.

For investors and licensing teams, the practical distinction is important:

• Biosimilars require analytical, pharmacokinetic and sometimes clinical comparability.
• Metformin generics generally rely on pharmaceutical equivalence and bioequivalence.
• Competition is therefore broader and faster once patents and exclusivity expire.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are moderate rather than high. Metformin hydrochloride is an established active ingredient with mature synthesis and a large global supplier base.

The principal operational risks are:

• Nitrosamine contamination and control strategy.
• API sourcing concentration.
• Validation of extended-release dissolution profiles.
• Scale-up and tablet robustness.
• Regulatory inspection findings.
• Supply continuity for public-sector procurement.

Intellectual-property barriers are limited for standard Glucophage products. A meaningful barrier could arise only from a newly patented formulation, delivery system, combination product or method of use. Such a patent would need to withstand validity and enforceability challenges and would not block ordinary metformin tablets.

What is the litigation and settlement status for Glucophage?

There is no current, widely recognized Paragraph IV litigation campaign that creates a material barrier to generic entry for the original Glucophage products. Historical patent disputes involving metformin formulations do not alter the present genericized status of the franchise.

Settlement agreements involving older Glucophage patents, where applicable, have no practical effect on ordinary generic metformin availability after expiration of the relevant rights. Current disputes are more likely to involve:

• Manufacturing quality.
• Product recalls.
• Labeling.
• Drug-supply contracts.
• New combination products.
• Patents covering other branded diabetes therapies.

How does Glucophage compare with newer diabetes drugs?

Factor	Glucophage/metformin	GLP-1 or GIP/GLP-1 drugs	SGLT2 inhibitors
Price	Very low in generic form	High	Moderate to high before generic entry
Weight effect	Neutral to modest loss	Substantial loss	Modest loss
Hypoglycemia risk	Low as monotherapy	Low unless combined	Low unless combined
Cardiovascular evidence	Long clinical experience	Strong for selected agents	Strong for selected agents
Kidney outcomes	Limited direct benefit	Varies by agent	Strong renal benefit for selected agents
Administration	Oral tablets	Mostly injectable, some oral options	Oral tablets
Patent risk	Minimal	High through the 2020s and beyond for leading products	Material, varying by product
Commercial growth	Volume-led	Value-led	Value-led

Metformin remains commercially durable because its cost and access profile are difficult to match. Its clinical share can decline in affluent markets while total global use continues to rise.

Key Takeaways

• Glucophage is the original branded metformin product, but the market is now overwhelmingly generic.
• Core patent and regulatory exclusivity has expired.
• No biosimilar pathway applies; competition occurs through ANDA-approved generics.
• Clinical research focuses on prevention, PCOS, cancer, COVID-19, aging and metabolic disease rather than improved diabetes efficacy.
• COVID-OUT produced a positive early-treatment result, but FDA approval for COVID-19 did not follow.
• Metformin is not FDA-approved for weight loss, anti-aging treatment, cancer prevention or PCOS.
• Global metformin demand should grow through 2030, while branded Glucophage revenue remains limited.
• The strongest commercial opportunities are in emerging markets, extended-release products, combination therapy and reliable low-cost supply.
• The main manufacturing concern is nitrosamine control, not synthesis complexity.
• Newer GLP-1, GIP/GLP-1 and SGLT2 therapies will pressure metformin clinically but are unlikely to displace it globally.

FAQs About Glucophage and Metformin

Is Glucophage still sold in the United States?

Generic metformin is broadly available in the United States. The original Glucophage brand has little commercial relevance compared with generic immediate-release and extended-release products.

Can metformin become an approved anti-aging drug?

A formal anti-aging approval would require clinical evidence using accepted disease or composite endpoints. Metformin has not received FDA approval for aging or longevity.

Does Glucophage have Orange Book patent protection?

The original Glucophage products do not have commercially meaningful active patent protection that prevents generic metformin entry. Product-specific formulation patents can affect individual products but do not restore protection to the core franchise.

Will GLP-1 drugs eliminate metformin use?

No. GLP-1 and GIP/GLP-1 therapies will reduce metformin’s relative role in some patients, especially those needing substantial weight loss or cardiovascular risk reduction. Low cost and broad access will preserve substantial metformin use.

What is the highest-value future indication for metformin?

The most commercially plausible opportunities are adjunctive use in metabolic disease, prevention in high-risk prediabetes populations and low-cost combination therapy. Cancer and aging indications have higher scientific uncertainty and would require strong randomized evidence.

References

1. American Diabetes Association Professional Practice Committee. (2024). “9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024.” Diabetes Care, 47(Supplement 1), S158-S178.

2. Bramante, C. T., Buse, J. B., Liebovitz, D. M., et al. (2022). “Metformin and ivermectin for COVID-19 in adults with overweight or obesity.” New England Journal of Medicine, 387(7), 599-610.

3. Diabetes Prevention Program Research Group. (2002). “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.” New England Journal of Medicine, 346(6), 393-403.

4. Fortune Business Insights. (2024). Metformin hydrochloride market size, share and industry analysis. Fortune Business Insights.

5. U.S. Food and Drug Administration. (2023). Glucophage and Glucophage XR prescribing information. FDA.

6. U.S. Food and Drug Administration. (2024). Metformin products: NDMA impurities and product recalls. FDA.

7. Grand View Research. (2024). Metformin hydrochloride market size, share and trends analysis report. Grand View Research.